173 related articles for article (PubMed ID: 38108281)
1. New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity.
Turek M; Różycka-Sokołowska E; Owsianik K; Bałczewski P
Mol Pharm; 2024 Jan; 21(1):18-37. PubMed ID: 38108281
[TBL] [Abstract][Full Text] [Related]
2. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential.
Turek M; Różycka-Sokołowska E; Koprowski M; Marciniak B; Bałczewski P
Mol Pharm; 2021 May; 18(5):1970-1984. PubMed ID: 33792313
[TBL] [Abstract][Full Text] [Related]
3. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Ahad A; Al-Mohizea AM; Al-Jenoobi FI; Aqil M
Drug Deliv; 2016; 23(2):579-90. PubMed ID: 25065883
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Sartans: a review.
Muszalska I; Sobczak A; Dołhań A; Jelińska A
J Pharm Sci; 2014 Jan; 103(1):2-28. PubMed ID: 24227012
[TBL] [Abstract][Full Text] [Related]
5. Research Progress in Pharmacological Mechanisms, Structure-Activity Relationship and Synthesis of Sartans.
Wang YF; Ren XY; Zhang W; Rao GW
Curr Med Chem; 2023; 30(20):2247-2266. PubMed ID: 36043743
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
7. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM; Lin MJ; Sun CM
Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
[TBL] [Abstract][Full Text] [Related]
8. Drug Treatment of Hypertension: Focus on Vascular Health.
Cameron AC; Lang NN; Touyz RM
Drugs; 2016 Oct; 76(16):1529-1550. PubMed ID: 27667708
[TBL] [Abstract][Full Text] [Related]
9. From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.
Matsoukas J; Apostolopoulos V; Zulli A; Moore G; Kelaidonis K; Moschovou K; Mavromoustakos T
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504092
[TBL] [Abstract][Full Text] [Related]
10. [Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers].
Roskiewicz F; Andriamanana I; Gras-Champel V; Andrejak M; Massy ZA
Nephrol Ther; 2007 Jun; 3(3):89-95. PubMed ID: 17540310
[TBL] [Abstract][Full Text] [Related]
11. Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.
Kelaidonis K; Ligielli I; Letsios S; Vidali VP; Mavromoustakos T; Vassilaki N; Moore GJ; Hoffmann W; Węgrzyn K; Ridgway H; Chasapis CT; Matsoukas JM
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176159
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.
Facciorusso A; Del Prete V; Crucinio N; Muscatiello N; Carr BI; Di Leo A; Barone M
J Gastroenterol Hepatol; 2015 Nov; 30(11):1643-50. PubMed ID: 25974743
[TBL] [Abstract][Full Text] [Related]
13. Modification of the Microtox® Basic Solid Phase Test: A new application for the ecotoxicological studies on poorly soluble antihypertensive drugs.
Turek M; Różycka-Sokołowska E; Owsianik K; Marciniak B; Bałczewski P
J Hazard Mater; 2020 Nov; 399():122839. PubMed ID: 32526424
[TBL] [Abstract][Full Text] [Related]
14. Rational Design and Synthesis of AT1R Antagonists.
Georgiou N; Gkalpinos VK; Katsakos SD; Vassiliou S; Tzakos AG; Mavromoustakos T
Molecules; 2021 May; 26(10):. PubMed ID: 34069122
[TBL] [Abstract][Full Text] [Related]
15. Reliability of captopril renography in patients under chronic therapy with angiotensin II (AT1) receptor antagonists.
Picciotto G; Sargiotto A; Petrarulo M; Rabbia C; De Filippi PG; Roccatello D
J Nucl Med; 2003 Oct; 44(10):1574-81. PubMed ID: 14530469
[TBL] [Abstract][Full Text] [Related]
16. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Happold C; Gorlia T; Nabors LB; Erridge SC; Reardon DA; Hicking C; Picard M; Stupp R; Weller M;
J Neurooncol; 2018 May; 138(1):163-171. PubMed ID: 29423540
[TBL] [Abstract][Full Text] [Related]
17. Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries.
Gadanec LK; Swiderski J; Apostolopoulos V; Kelaidonis K; Vidali VP; Canko A; Moore GJ; Matsoukas JM; Zulli A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139391
[TBL] [Abstract][Full Text] [Related]
18. NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAROXETINE), SNRIS (VENLAFAXINE) AND METFORMIN: THE MOST PROBABLE EXPLANATION FOR THE RISING SKIN CANCER INCIDENCE.
Tchernev G
Georgian Med News; 2023 Jun; (339):24-32. PubMed ID: 37522769
[TBL] [Abstract][Full Text] [Related]
19. METATYPICAL BCCS OF THE NOSE TREATED SUCCESSFULLY VIA BILOBED TRANSPOSITION FLAP: NITROSAMINES IN ACES (ENALAPRIL), ARBS (LOSARTAN) AS POSSIBLE SKIN CANCER KEY TRIGGERING FACTOR.
Tchernev G; Kordeva S; Lozev I
Georgian Med News; 2023 Feb; (335):22-25. PubMed ID: 37042583
[TBL] [Abstract][Full Text] [Related]
20. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
